The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move that strengthens its position in the companion diagnostics market, Agilent Technologies announced it has received FDA approval for its PD-L1 IHC 28-8 pharmDx assay. This test will serve as a companion diagnostic to identify patients eligible for cancer treatments based on the drug OPDIVO. According to reports, this approval supports Agilent's strategy to expand recurring revenue streams and bolster its presence in the oncology sector.
This regulatory milestone arrives as analyst assessments suggest the stock remains undervalued by approximately 13.9%. Per market data, Agilent (A) shares closed at $138.57 on July 24, 2026, with the session seeing a range between a low of $138.02 and a high of $140.88. The FDA approval is viewed as a positive fundamental driver for the company, complementing the stock's recent market momentum.
Traders should watch for price stability around the $138.02 support level, representing the daily low as of the July 24, 2026 close. While the upcoming economic calendar shows no immediate healthcare-specific catalysts, the focus remains on how this regulatory clearance will translate into market share gains for Agilent in the advanced diagnostics space.